1. Academic Validation
  2. Identification and Evaluation of the Minimum Unit of a KALA Peptide Required for Gene Delivery and Immune Activation

Identification and Evaluation of the Minimum Unit of a KALA Peptide Required for Gene Delivery and Immune Activation

  • J Pharm Sci. 2017 Oct;106(10):3113-3119. doi: 10.1016/j.xphs.2017.05.014.
Naoya Miura 1 Kota Tange 2 Yuta Nakai 2 Hiroki Yoshioka 3 Hideyoshi Harashima 4 Hidetaka Akita 5
Affiliations

Affiliations

  • 1 Department of Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo City, Hokkaido, Japan.
  • 2 NOF CORPORATION, 3-3 Chidori-cho, Kawasaki-ku, Kawasaki City, Kanagawa, Japan.
  • 3 Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba City, Chiba, Japan.
  • 4 Department of Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo City, Hokkaido, Japan. Electronic address: harasima@pharm.hokudai.ac.jp.
  • 5 Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba City, Chiba, Japan. Electronic address: akitahide@chiba-u.jp.
Abstract

The KALA peptide (WEAKLAKALAKALAKHLAKALAKALKA) is an amphiphilic peptide that forms an α-helical structure at physiological pH. We previously reported that, when a plasmid DNA-encapsulating liposomal membrane is modified with the KALA peptide, transgene expression and immune activation are facilitated in bone marrow-derived dendritic cells (BMDCs). However, the minimum unit of the KALA peptide and the importance of its secondary structure for these activities are not completely known at this time. We herein report on the identification of the minimum unit of the KALA peptide (short-KALA) required for activity, as determined by the stepwise removal of "K-A-L-A" units. We evaluated the activities of 4 types of short-KALAs by modifying plasmid DNA-encapsulating multi-functional envelop-type nano devices. Among the Peptides tested, a short-KALA3 (WEAKLAKALAKALA) was the shortest KALA peptide that could form an α-helical structure, as well as to elicit transgene expression and immune activation in BMDCs. Furthermore, the function of the short-KALA3 as an inducer of cellular uptake was retained, while uptake was completely lost in more shortened versions of KALA (short KALA4), in that transgene expression and immunological activation were both completely lost. These collective data show that the KALA peptide must form an α-helical structure to induce cellular uptake in BMDCs.

Keywords

circular dichroism; gene vectors; liposomes; non-viral gene delivery; peptides; vaccine adjuvants; vaccine delivery.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P2530
    Peptide